You are here: Industry Insights > Keytruda

News List

FDA Approves Merck’s KEYTRUDA® as Adjuvant Treatment for Patients with Stage IIB or IIC Melanoma AmericanPharmaceuticalReview
December 07, 2021
Merck announced that the FDA has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
Merck’s Keytruda obtains FDA approval as adjuvant therapy for melanoma patients Pharmaceutical-Business-Review
December 07, 2021
Merck’s anti-PD-1 therapy, Keytruda, has obtained approval from the US Food and Drug Administration (FDA) as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12 years and above.
European Commission Approves KEYTRUDA Plus LENVIMA for Patients With Endometrial Carcinoma AmericanPharmaceuticalReview
December 02, 2021
Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the treatment of advance...
Stingthera, Merck to collaborate to analyse SNX281 with Keytruda Pharmaceutical-Business-Review
November 04, 2021
SNX281 is Stingthera’s small molecule agonist of the Stimulator of Interferon Genes (STING) protein.
Gilead and Merck collaborate for breast cancer combination treatment Pharmaceutical-Technology
November 01, 2021
Gilead Sciences and Merck (MSD) have signed a clinical trial partnership and supply agreement to assess the efficacy of the former’s Trodelvy (sacituzumab govitecan-hziy) along with...
EC approves Merck’s Keytruda and chemotherapy combination for TNBC patients Pharmaceutical-Business-Review
October 28, 2021
The European Commission (EC) has approved Merck’s Keytruda (pembrolizumab) plus chemotherapy combination to treat triple-negative breast cancer (TNBC) patients.
FDA approves Keytruda plus Lenvima for advanced kidney cancer pharmatimes
August 13, 2021
The US Food and Drug Administration (FDA) has approved a combination of MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Eisai’s Lenvima (lenvatinib) for the first-line treatment of adult patients with advanced renal cell carcinoma ...
Merck’s Keytruda receives FDA priority review in renal cell cancer pharmaceutical-technology
August 12, 2021
The US Food and Drug Administration (FDA) has granted priority review to Merck’s (MSD) new supplemental biologics license application (sBLA) for Keytruda (pembrolizumab) as adjuvant therapy to treat renal cell carcinoma (RCC) patients.
US clears Keytruda, Lenvima combo in first-line kidney cancer firstwordpharma
August 12, 2021
The FDA announced Wednesday that it approved the combination of Merck & Co.'s anti-PD-1 therapy Keytruda (pembrolizumab) and Eisai's oral multi-kinase inhibitor Lenvima (lenvatinib) as a first-line treatment for adults with advanced renal cell carcinoma.
FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma drugs
July 29, 2021
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page